bit.bio
- Health & Biotech
- Cambridge, GB
- Private
- bit.bio
Cambridge biotech making human cell models, engineered from reprogrammed cells for drug discovery and research.
$25MEquity raised in 2025–20262025 — · 2026 $25M · 1 equity round
$25MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 1 source
Earlier rounds not yet sourced. bit.bio raised before 4 Nov 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series DAmount$25MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 2
- Jonathan Milner
- M&G Investments
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
TractianEnterprise · $130M in 2025–2026Shared: M&G InvestmentsPhysicsXAI Apps · $435M in 2025–2026Shared: M&G InvestmentsNearfield InstrumentsDeep Tech · $380M in 2025–2026Shared: M&G InvestmentsAMBOSSHealth · $259M in 2025–2026Shared: M&G InvestmentsMainspring EnergyEnergy · $258M in 2025–2026Shared: M&G InvestmentsPixxelDefense · $100M in 2025–2026Shared: M&G Investments
Also in the Cambridge hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. bit.bio and its logo are trademarks of their owners, used here for identification only.
